{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T20:07:10Z","timestamp":1783282030946,"version":"3.54.6"},"reference-count":45,"publisher":"Index Copernicus","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pol Przegl Chir"],"published-print":{"date-parts":[[2025,11,13]]},"abstract":"<b>Introduction:<\/b> Pancreatic cancer is still an unresolved, significant diagnostic and clinical problem. An ideal tumor marker with a high sensitivity, organ specificity, and prognostic value that correlates with tumor stages and eliminates the imperfection of preoperative serum carbohydrate antigen 19-9 (CA 19-9) concentration is still being sought.<b>Aim:<\/b> This study aimed to conduct a comparative analysis expression of genes <i>KRAS, DPM1, ACRV1<\/i>, and <i>MBD3L2<\/i> in the saliva of patients with pancreatic cancer (PC) and a control group (CG).<b>Material and methods:<\/b> The study was performed on a group of 55 patients. Group 1 consisted of 44 patients with PC, group 2 (CG) consisted of 11 individuals who were recruited among patients operated on for non-inflammatory cholelithiasis. Group 1 was divided into 2 subgroups group 1a, 19 patients with resectable pancreatic tumors, and group 1b, 25 patients with unresectable pancreatic tumors. The saliva samples were taken from patients twice, before surgery and 10 days after surgery, and the expression of genes <i>KRAS, DPM1, ACRV1<\/i>, and <i>MBD3L2<\/i> in the saliva was evaluated. Gene expression at the transcriptional level was analyzed by assessing the number of mRNA copies using the reverse transcriptase reaction and polymerase chain reaction (RT-PCR).<b>Results:<\/b> The revealed expression of genetic cancer biomarkers (CB) (<i>KRAS, DPM1, ACRV1, MBD3L2<\/i>) in saliva was statistically significantly higher in the PC group in comparison to CG. There was a statistically significant decrease in the <i>KRAS<\/i> gene expression and a statistically significant increase in the <i>MBD3L2<\/i> expression in patients in subgroup 1a, 10 days after resection procedures. The revealed serum concentration of CA 19-9 was significantly higher in subgroup 1b in comparison to subgroup 1a. Although higher gene expression of <i>KRAS, DPM1<\/i>, and <i>MBD3L2 <\/i>was observed in subgroup 1b, no statistical significance was obtained. A statistically significant correlation between <i>DPM1<\/i> expression and serum CA 19-9 level in the PC group was observed. There were statistically significant differences in <i>KRAS <\/i>and <i>DPM1<\/i> expression depending on the tumor stage in the TNM\/UICC classification regarding to T and N category. A significant difference in <i>MBD3L2<\/i> expression was observed in N category. A statistically significant increase in the expression of <i>KRAS, DPM1<\/i>, and <i>MBD3L2 <\/i>was observed in the case of neoplastic infiltration of blood vessels, and a significant increase in the expression of <i>KRAS<\/i> and <i>MBD3L2 <i\/>in the case of neoplastic infiltration of nerve fibers.<b>Conclusions:<\/b> Presented findings suggest the usefulness of the salivary transcriptome profiles in distinguishing patients with PC from healthy controls but its usefulness in the differential diagnosis between resectable and unresectable PC is limited. However, more studies on a large population are needed to support our result.<\/ns3:p>","DOI":"10.5604\/01.3001.0055.4390","type":"journal-article","created":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T10:56:24Z","timestamp":1767092184000},"page":"33-47","source":"Crossref","is-referenced-by-count":1,"title":["The expression of genes KRAS, DPM1, ACRV1, and MBD3L2 in the saliva as potential tumor markers in the detection of pancreatic cancer"],"prefix":"10.5604","volume":"97","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8929-9536","authenticated-orcid":false,"given":"Jakub","family":"Ciosek","sequence":"first","affiliation":[{"name":"Department of Gastrointestinal Surgery, Medical University of Silesia, Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9107-8633","authenticated-orcid":false,"given":"Daria","family":"Dranka-Bojarowska","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, Medical University of Silesia, Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6683-1101","authenticated-orcid":false,"given":"Adam","family":"Lewi\u0144ski","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, Medical University of Silesia, Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0862-9666","authenticated-orcid":false,"given":"Pawe\u0142","family":"Lampe","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, Medical University of Silesia, Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3689","reference":[{"key":"633724r1","doi-asserted-by":"crossref","unstructured":"Siegel R.L., Miller K.D., Jemal A.: Cancer statistics, 2019. CA Cancer J Clin.,2019; 69(1): 7\u201334. doi: 10.3322\/caac.21551.","DOI":"10.3322\/caac.21551"},{"key":"633724r2","doi-asserted-by":"crossref","unstructured":"Lepage C., Capocaccia R., Hackl M. et al.: EUROCARE-5 Working Group:.Survival in patients with primary liver cancer, gallbladder and extrahepaticbiliary tract cancer and pancreatic cancer in Europe 1999\u20132007: Resultsof EUROCARE-5. Eur J Cancer., 2015; 51(15): 2169\u20132178. doi: 10.1016\/j.ejca.2015.07.034.","DOI":"10.1016\/j.ejca.2015.07.034"},{"key":"633724r3","doi-asserted-by":"crossref","unstructured":"Maisonneuve P., Lowenfels A.B.: Epidemiology of pancreatic cancer: an update.Dig Dis., 2010; 28(4\u20135): 645\u2013656. doi: 10.1159\/000320068.","DOI":"10.1159\/000320068"},{"key":"633724r4","doi-asserted-by":"crossref","unstructured":"Krejs G.J.: Pancreatic cancer: epidemiology and risk factor. Dig Dis., 2010;28(2): 355\u2013358. doi: 10.1159\/000319414.","DOI":"10.1159\/000319414"},{"key":"633724r5","unstructured":"Hersz\u00e9nyi L., Tulassay Z.: Epidemiology of gastrointestinal and liver tumors.Eur Rev Med Pharmacol Sci., 2010, 14(4): 249\u2013258."},{"key":"633724r6","doi-asserted-by":"crossref","unstructured":"Vincent A., Herman J., Schulick R., Hruban R.H., Goggins M.: Pancreatic cancer,Lancet., 2011; 378(9791): 607\u2013620. doi: 10.1016\/S0140-6736(10)62307-0.","DOI":"10.1016\/S0140-6736(10)62307-0"},{"key":"633724r7","doi-asserted-by":"crossref","unstructured":"Liu H.J., Guo Y.Y., Li D.J.: Predicting novel salivary biomarkers for the detectionof pancreatic cancer using biological feature-based classification. PatholRes Pract., 2017; 213(4): 394\u2013399. doi: 10.1016\/j.prp.2016.09.017.","DOI":"10.1016\/j.prp.2016.09.017"},{"key":"633724r8","doi-asserted-by":"crossref","unstructured":"Kamisawa T., Wood L.D., Itoi T., Takaori K.: Pancreatic cancer. Lancet., 2016;388(10039): 73\u201385. doi: 10.1016\/S0140-6736(16)00141-0.","DOI":"10.1016\/S0140-6736(16)00141-0"},{"key":"633724r9","unstructured":"Goggins M., Koopmann J., Yang D., Canto M.I., Hruban R.: National Academyof Clinical Biochemistry (NACB) Guidelines for the Use of Tumor Markersin Pancreatic Ductal Adenocarcinoma. https:\/\/www.nacb.org\/lmpg\/tumor\/chp3i_pancreatic.pdf (24.12.2024)."},{"key":"633724r10","doi-asserted-by":"crossref","unstructured":"Ballehaninna U.K., Chamberlain R.S.: Serum CA 19-9 as a Biomarker for PancreaticCancer-A Comprehensive Review. Indian J Surg Oncol., 2011; 2(2):88\u2013100. doi: 10.1007\/s13193-011-0042-1.","DOI":"10.1007\/s13193-011-0042-1"},{"key":"633724r11","unstructured":"Kannagi R.: Carbohydrate antigen sialyl Lewis and its pathophysiological significanceand induction mechanism in cancer progression. Chang Gung MedJ., 2007; 30(3): 189\u2013209."},{"key":"633724r12","unstructured":"Ballehaninna U.K., Chamberlain R.S.: The clinical utility of serum CA 19-9in the diagnosis, prognosis and management of pancreatic adenocarcinoma:An evidence based appraisal. J Gastrointest Oncol., 2012; 3(2): 105\u2013119. doi:10.3978\/j.issn.2078-6891.2011.021."},{"key":"633724r13","doi-asserted-by":"crossref","unstructured":"Molina V., Visa L., Conill C. et al.: CA 19-9 in pancreatic cancer: retrospectiveevaluation of patients with suspicion of pancreatic cancer. Tumor Biol., 2012;33(3): 799\u2013807. doi: 10.1007\/s13277-011-0297-8.","DOI":"10.1007\/s13277-011-0297-8"},{"key":"633724r14","doi-asserted-by":"crossref","unstructured":"Sakorafas G.H., Tsiotou A.G., Tsiotos G.G.: Molecular biology of pancreaticcancer; oncogenes, tumour suppressor genes, growth factors, and their receptorsfrom a clinical perspective. Cancer Treat Rev., 2000; 26(1): 29\u201352. doi:10.1053\/ctrv.1999.0144.","DOI":"10.1053\/ctrv.1999.0144"},{"key":"633724r15","doi-asserted-by":"crossref","unstructured":"Chang J.C., Kundranda M.: Novel Diagnostic and Predictive Biomarkers inPancreatic Adenocarcinoma. Int J Mol Sci., 2017; 18(3): 667. doi: 10.3390\/ijms18030667.","DOI":"10.3390\/ijms18030667"},{"key":"633724r16","unstructured":"Lee Y.H., Wong D.T.: Saliva: an emerging biofluid for early detection of diseases.Am J Dent., 2009; 22(4): 241\u2013248."},{"key":"633724r17","doi-asserted-by":"crossref","unstructured":"Zhang L., Farrell J.J., Zhou H. et al.: Salivary transcriptomic biomarkers fordetection of resectable pancreatic cancer. Gastroenterology., 2010; 138(3):949\u2013957. doi: 10.1053\/j.gastro.2009.11.010.","DOI":"10.1053\/j.gastro.2009.11.010"},{"key":"633724r18","doi-asserted-by":"crossref","unstructured":"Xie Z., Yin X., Gong B. et al.: Salivary microRNAs show potential as a noninvasivebiomarker for detecting resectable pancreatic cancer. Cancer Prev Res.,2015; 8(2): 165\u2013173. doi: 10.1158\/1940-6207.CAPR-14-0192.","DOI":"10.1158\/1940-6207.CAPR-14-0192"},{"key":"633724r19","doi-asserted-by":"crossref","unstructured":"Wang X., Kaczor-Urbanowicz K.E., Wong D.T.W.: Salivary biomarkers in cancerdetection. Med Oncol., 2017; 34(1): 7. doi: 10.1007\/s12032-016-0863-4.","DOI":"10.1007\/s12032-016-0863-4"},{"key":"633724r20","doi-asserted-by":"crossref","unstructured":"Rahib L., Smith B.D., Aizenberg R. et al.: Projecting cancer incidence and deathsto 2030: the unexpected burden of thyroid, liver, and pancreas cancers inthe United States. Cancer Res., 2014; 74(11): 2913\u20132921. doi: 10.1158\/0008-5472.CAN-14-0155.","DOI":"10.1158\/0008-5472.CAN-14-0155"},{"key":"633724r21","doi-asserted-by":"crossref","unstructured":"Wray C.J., Ahmad S.A., Matthews J.B., Lowy A.M.: Surgery for pancreatic cancer:recent controversies and current practice. Gastroenterology., 2005; 128(6):1626\u20131641. doi: 10.1053\/j.gastro.2005.03.035.","DOI":"10.1053\/j.gastro.2005.03.035"},{"key":"633724r22","doi-asserted-by":"crossref","unstructured":"Abraham J.E., Maranian M.J., Spiteri I. et al.: Saliva samples are a viable alternativeto blood samples as a source of DNA for high throughput genotyping.BMC Med Genomics., 2012; 5: 19. doi: 10.1186\/1755-8794-5-19.","DOI":"10.1186\/1755-8794-5-19"},{"key":"633724r23","doi-asserted-by":"crossref","unstructured":"Vogelstein B., Papadopoulos N., Velculescu V.E. et al.: Cancer genome landscapes.Science., 2013; 339(6127): 1546\u20131558. doi: 10.1126\/science.1235122.","DOI":"10.1126\/science.1235122"},{"key":"633724r24","doi-asserted-by":"crossref","unstructured":"Felsenstein M., Hruban R., Wood L.D.: New Developments in the MolecularMechanisms of Pancreatic Tumorigenesis. Adv Anat Pathol., 2018; 25(2):131\u2013142. doi: 10.1097\/PAP.0000000000000172.","DOI":"10.1097\/PAP.0000000000000172"},{"key":"633724r25","doi-asserted-by":"crossref","unstructured":"Aguirre A.J., Collisson E.A.: Advances in the Genetics and Biology of PancreaticCancer. Cancer J., 2017; 23(6): 315\u2013320. doi: 10.1097\/PPO.0000000000000286.","DOI":"10.1097\/PPO.0000000000000286"},{"key":"633724r26","doi-asserted-by":"crossref","unstructured":"Steinberg W.M., Gelfand R., Anderson K.K. et al.: Comparison of the sensitivityand specificity of the CA19-9 and carcinoembryonic antigen assays indetecting cancer of the pancreas. Gastroenterology., 1986; 90(2): 343\u2013349. doi:10.1016\/0016-5085(86)90930-3.","DOI":"10.1016\/0016-5085(86)90930-3"},{"key":"633724r27","doi-asserted-by":"crossref","unstructured":"Kim Y.C., Kim H.J., Park J.H. et al.: Can preoperative CA19-9 and CEA levelspredict the resectability of patients with pancreatic adenocarcinoma? J GastroenterolHepatol., 2009; 24(12): 1869\u20131875. doi: 10.1111\/j.1440-1746.2009.05935.x.","DOI":"10.1111\/j.1440-1746.2009.05935.x"},{"key":"633724r28","doi-asserted-by":"crossref","unstructured":"O\u2019Reilly D., Fou L., Hasler E. et al.: Diagnosis and management of pancreaticcancer in adults: A summary of guidelines from the UK National Institutefor Health and Care Excellence. Pancreatology., 2018; 18(8): 962\u2013970. doi:10.1016\/j.pan.2018.09.012.","DOI":"10.1016\/j.pan.2018.09.012"},{"key":"633724r29","doi-asserted-by":"crossref","unstructured":"Park J.K., Paik W.H., Ryu J.K. et al.: Clinical significance and revisiting themeaning of CA 19-9 blood level before and after the treatment of pancreaticductal adenocarcinoma: Analysis of 1,446 patients from the pancreatic cancercohort in a single institution. PLoS One., 2013; 8(11): e78977. doi: 10.1371\/journal.pone.0078977.","DOI":"10.1371\/journal.pone.0078977"},{"key":"633724r30","doi-asserted-by":"crossref","unstructured":"Perets R., Greenberg O., Shentzer T. et al.: Mutant KRAS Circulating TumorDNA Is an Accurate Tool for Pancreatic Cancer Monitoring. Oncologist., 2018;23(5): 566\u2013572. doi: 10.1634\/theoncologist.2017-0467.","DOI":"10.1634\/theoncologist.2017-0467"},{"key":"633724r31","doi-asserted-by":"crossref","unstructured":"van Manen L., Groen J.V., Putter H. et al.: Elevated CEA and CA19-9 serumlevels independently predict advanced pancreatic cancer at diagnosis. Biomarkers.,2020; 25(2): 186\u2013193. doi: 10.1080\/1354750X.2020.1725786.","DOI":"10.1080\/1354750X.2020.1725786"},{"key":"633724r32","doi-asserted-by":"crossref","unstructured":"Valsangkar N.P., Bush D.M., Michaelson J.S. et al.: N0\/N1, PNL, or LNR? The effect oflymph node number on accurate survival prediction in pancreatic ductal adenocarcinoma.Gastrointest Surg., 2013; 17(2): 257\u2013266. doi: 10.1007\/s11605-012-1974-7.","DOI":"10.1007\/s11605-012-1974-7"},{"key":"633724r33","doi-asserted-by":"crossref","unstructured":"Pavlidis T.E., Pavlidis E.T., Sakantamis A.K.: Current opinion on lymphadenectomyin pancreatic cancer surgery. Hepatobiliary Pancreat Dis Int., 2011;10(1): 21\u201325. doi: 10.1016\/s1499-3872(11)60002-7.","DOI":"10.1016\/S1499-3872(11)60002-7"},{"key":"633724r34","doi-asserted-by":"crossref","unstructured":"Tas F., Sen F., Odabas H. et al.: Performance status of patients is the major prognosticfactor at allstages of pancreatic cancer. Int J Clin Oncol., 2013; 18(5):839\u2013846. doi: 10.1007\/s10147-012-0474-9.","DOI":"10.1007\/s10147-012-0474-9"},{"key":"633724r35","unstructured":"Dranka-Bojarowska D., Lekstan A., Olakowski M. et al.: The assessment of serumconcentration of adiponectin, leptin and serum carbohydrate antigen-19.9in patients with pancreatic cancer and chronic pancreatitis. J Physiol Pharmacol.,2015; 66(5): 653\u2013663."},{"key":"633724r36","unstructured":"Dranka-Bojarowska D., Lewinski A., Lekstan A. et al.: The assessment of serumand diagnostic peritoneal lavage concentration of matrix metalloproteinase-2,matrix metalloproteinase-9, carbohydrate antigen 19-9, and carcinoembryonicantigen in patients with pancreatic cancer and chronic pancreatitis. J PhysiolPharmacol., 2020; 71(5). doi: 10.26402\/jpp.2020.5.09."},{"key":"633724r37","doi-asserted-by":"crossref","unstructured":"Bilici A.: Prognostic factors related with survival in patients with pancreaticadenocarcinoma. World J Gastroenterol., 2014; 20(31): 10802\u201310812. doi:10.3748\/wjg.v20.i31.10802.","DOI":"10.3748\/wjg.v20.i31.10802"},{"key":"633724r38","doi-asserted-by":"crossref","unstructured":"Haglund C., Lindgren J., Roberts P.J., Nordling S.: Gastrointestinal cancer-associated antigen CA 19-9 in histological specimens of pancreatictumors and pancreatitis. Br J Cancer., 1986; 53(2): 189\u2013195. doi: 10.1038\/bjc.1986.34.","DOI":"10.1038\/bjc.1986.34"},{"key":"633724r39","unstructured":"Itzkowitz S.H., Yuan M., Fukushi Y. et al.: Immunohistochemical comparisonof Lea, monosialosyl Lea (CA 19-9), and disialosyl Lea antigens in human colorectaland pancreatic tissues. Cancer Res., 1988; 48(13): 3834\u20133842."},{"key":"633724r40","doi-asserted-by":"crossref","unstructured":"Yang M., Zhang C.Y.: Diagnostic biomarkers for pancreatic cancer: An update.World J Gastroenterol., 2021; 27(45): 7862\u20137865. doi: 10.3748\/wjg.v27.i45.7862..","DOI":"10.3748\/wjg.v27.i45.7862"},{"key":"633724r41","doi-asserted-by":"crossref","unstructured":"Buscail L., Bournet B., Cordelier P.: Role of oncogenic KRAS in the diagnosis,prognosis and treatment of pancreatic cancer. Nat Rev Gastroenterol Hepatol.,2020; 17(3): 153\u2013168. doi: 10.1038\/s41575-019-0245-4.","DOI":"10.1038\/s41575-019-0245-4"},{"key":"633724r42","doi-asserted-by":"crossref","unstructured":"Bournet B., Buscail C., Muscari F., Cordelier P., Buscail L.: Targeting KRAS fordiagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities.Cancer., 2016; 54: 75\u201383. doi: 10.1016\/j.ejca.2015.11.012.","DOI":"10.1016\/j.ejca.2015.11.012"},{"key":"633724r43","doi-asserted-by":"crossref","unstructured":"Asai Y., Itoi T., Sugimoto M. et al.: Elevated Polyamines in Saliva ofPancreatic Cancer. Cancers (Basel)., 2018; 10(2): 43. doi: 10.3390\/cancers10020043.","DOI":"10.3390\/cancers10020043"},{"key":"633724r44","doi-asserted-by":"crossref","unstructured":"Nose D., Sugimoto M., Muta T., Miura S.I.: Salivary Polyamines Help DetectHigh-Risk Patients with Pancreatic Cancer: A Prospective Validation Study.Int J Mol Sci., 2023; 24(3): 2998. doi: 10.3390\/ijms24032998.","DOI":"10.3390\/ijms24032998"},{"key":"633724r45","doi-asserted-by":"crossref","unstructured":"Chiabotto G., Gallo S., Camussi G.: Salivary Extracellular Vesicle-AssociatedexRNA as Cancer Biomarker. Cancers (Basel)., 2019; 11(7): 891. doi: 10.3390\/cancers11070891.","DOI":"10.3390\/cancers11070891"}],"container-title":["Polish Journal of Surgery"],"original-title":[],"link":[{"URL":"https:\/\/ppch.pl\/gicid\/pdf\/01.3001.0055.4390","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ppch.pl\/gicid\/pdf\/01.3001.0055.4390","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T09:29:18Z","timestamp":1768469358000},"score":1,"resource":{"primary":{"URL":"https:\/\/ppch.pl\/gicid\/01.3001.0055.4390"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,13]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.5604\/01.3001.0055.4390","relation":{},"ISSN":["0032-373X","2299-2847"],"issn-type":[{"value":"0032-373X","type":"print"},{"value":"2299-2847","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,13]]}}}